NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.…
NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
NervGen Pharma (NASDAQ: NGEN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 1.845 USD on 20 November 2026, down 31.5% over 52 weeks. Its 52-week range is 1.280 USD to 6.300 USD: the price is 70.7% below the high and 44.1% above the low.
Its market capitalisation is 198.55M USD.
NervGen Pharma reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 80.12M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.